<DOC>
	<DOCNO>NCT00291798</DOCNO>
	<brief_summary>The objective present clinical investigation determine whether hormonal therapy give preoperatively able reduce tumor size extent facilitate breast-conserving procedure .</brief_summary>
	<brief_title>Neoadjuvant Endocrinotherapy Breast Cancer ( Mamma Carcinoma ) With Exemestane</brief_title>
	<detailed_description>This open , prospective multicenter Phase II pilot trial investigate efficacy exemestane , 25 mg daily 4 month , postmenopausal woman primary breast cancer , measure term clinical response</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Histologically verify breast cancer ( punch biopsy ) , establish HER2/neu status Postmenopausal patient ( &gt; 1 year follow outset menopause and/or postmenopausal hormonal profile ) Clinical staging : T2 ( &gt; 3 cm ) , T3 , T4ac , N01 Hormone receptor positivity , i.e . estrogen and/or progesterone receptor &gt; 10 fmol/mg cytosolic protein ERICApositive and/or PgRICApositive . Positivity + ( lowgrade ) one hormone receptor eligible presence positivity hormone receptor . internal contraindication life expectation &gt; 6 month write informed consent premenopausal patient patient clearly indicate menopausal status manifest second malignant tumor ( except basalioma situ carcinoma cervix uterus ) uncontrolled internal disease i.e . diabetes mellitus , cardiac disease ( NYHA III/IV ) thromboembolic disease inflammatory mamma carcinoma existence distant metastasis former simultaneously therapy antioestrogens , aromatase inhibitor , cytostatics radiotherapy corticosteroid study ( except inhalant application ) lack compliance</criteria>
	<gender>Female</gender>
	<minimum_age>59 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>pilot study</keyword>
	<keyword>exemestane</keyword>
	<keyword>endocrinotherapy</keyword>
	<keyword>mamma carcinoma</keyword>
	<keyword>neoadjuvant</keyword>
	<keyword>ABCSG</keyword>
	<keyword>17</keyword>
</DOC>